Market Outlook

The U.S. Minimally Invasive Oncology Devices Market is estimated at approximately USD 11.80 billion in 2025 and is projected to reach around USD 38.15 billion by 2035, expanding at a strong CAGR of 12.45% during the forecast period 2026–2035. Historical market analysis covers 2021–2024, with the market estimated at approximately USD 7.34 billion in 2021, USD 8.10 billion in 2022, USD 9.20 billion in 2023, and USD 10.49 billion in 2024. Values in this report are expressed in USD billions.

The market encompasses medical devices and procedural technologies used to diagnose, access, visualize, remove, destroy, embolize, or locally treat malignant solid tumors using approaches designed to minimize surgical trauma. The commercial scope includes robotic-assisted oncology surgery systems and instruments, laparoscopic oncology devices, endoscopic and endoluminal therapeutic systems, percutaneous tumor ablation technologies, microwave and radiofrequency ablation, cryoablation, irreversible electroporation, high-intensity focused ultrasound, histotripsy, embolization and radioembolization delivery technologies, image-guided navigation platforms, oncology biopsy and access devices, and associated procedure-specific consumables.

Standalone external-beam radiation therapy equipment, systemic pharmaceutical therapies, diagnostic imaging systems without direct interventional use, and conventional open-surgery instrumentation are excluded from the core market definition. This distinction is important because minimally invasive oncology is increasingly functioning as a discrete procedural ecosystem positioned between traditional open surgery, systemic oncology, interventional radiology, therapeutic endoscopy, and highly targeted local tumor therapy.

The commercial opportunity is supported by the scale of the U.S. cancer burden. Approximately 2.04 million new cancer cases were expected to be diagnosed in the United States in 2025, with around 618,120 cancer deaths. Nearly 39% of Americans are expected to receive a cancer diagnosis during their lifetime. The U.S. additionally had more than 18 million people living with a history of cancer in recent national prevalence estimates, expanding the population requiring surveillance, repeat intervention, local recurrence management, metastasis-directed therapy, and survivorship care.

Minimally invasive oncology devices are benefiting from a fundamental change in cancer treatment economics. Hospital systems increasingly evaluate whether an intervention can reduce operating-room occupancy, inpatient length of stay, transfusion requirements, complication exposure, postoperative intensive-care utilization, readmissions, and total recovery time. Technologies capable of converting an inpatient cancer procedure into a shorter-stay or outpatient episode can consequently create economic value even when their individual device cost is higher than conventional alternatives.

The market’s projected 12.45% CAGR reflects more than procedure-volume expansion. Revenue growth will increasingly be generated by higher-value robotic platforms, disposable robotic instrumentation, tumor-specific ablation consumables, navigation technologies, advanced energy systems, image-integrated workflows, radioembolization devices, focal prostate treatment, non-thermal tumor destruction, and repeatable intervention models for metastatic disease.

By 2035, minimally invasive oncology is expected to represent a substantially larger component of U.S. procedural cancer management as treatment moves from organ-removing surgery toward tissue-sparing, image-guided, focal, robotic, and function-preserving intervention wherever clinically appropriate.

 

Introduction

According to the U.S. Minimally Invasive Oncology Devices Market Report, the market is positioned at the intersection of surgical oncology, interventional oncology, gastroenterology, pulmonology, urology, gynecology, radiology, and advanced imaging. Unlike a conventional surgical-device market, purchasing decisions frequently involve multidisciplinary tumor boards, service-line executives, interventional radiologists, oncologic surgeons, anesthesiologists, pathologists, radiologists, finance teams, and hospital value-analysis committees.

Cancer remains one of the largest sources of medical expenditure in the United States. National cancer-care expenditures were estimated at approximately USD 208.9 billion in 2020, while demographic projections indicate that U.S. cancer-related medical costs could approach USD 246 billion by 2030 based on population growth and aging alone. Against this background, providers have a strong economic incentive to identify treatment pathways that maintain clinical quality while reducing procedural morbidity and resource intensity.

The underlying procedure base is broad. Minimally invasive approaches are now routinely considered in prostatectomy, nephrectomy, partial nephrectomy, colectomy, hysterectomy, lung resection, liver tumor ablation, renal tumor ablation, metastatic lesion treatment, pancreatic and biliary interventions, endoscopic tumor resection, bronchoscopy-based lesion access, percutaneous biopsy, hepatic embolization, selective internal radiation therapy, focal prostate ablation, and selected palliative procedures.

The commercial characteristics of these procedures differ materially. Robotic oncology creates significant capital-system and recurring instrument revenue. Ablation generates generator-platform revenue combined with high-value probes, applicators, electrodes, needles, and disposables. Embolization creates recurring catheter, guidewire, microsphere, delivery-set, and navigation demand. Therapeutic endoscopy depends on visualization platforms and procedure-specific accessories. Biopsy and percutaneous intervention create large recurring consumable volumes with lower individual average selling prices.

Hospital procurement is therefore shifting from isolated device contracting toward procedural-platform contracting. Large integrated delivery networks increasingly evaluate whether vendors can support multiple phases of cancer care, including lesion access, intraoperative visualization, tissue acquisition, navigation, treatment, ablation-zone confirmation, workflow analytics, instrument supply, clinical education, and capital service.

The U.S. environment is particularly favorable for premium minimally invasive oncology technologies because of its high concentration of National Cancer Institute-designated centers, academic medical centers, integrated health systems, interventional radiology programs, robotic surgery programs, specialist physician networks, clinical trials, and sophisticated reimbursement infrastructure.

The opportunity nevertheless remains selective rather than universal. Technologies must demonstrate more than technical feasibility. High-value adoption increasingly depends on evidence showing appropriate patient selection, reproducible oncologic outcomes, acceptable recurrence rates, reduced complications, preservation of organ function, shorter recovery, attractive hospital economics, and integration into existing clinical pathways.

 

Key Market Drivers: What Is Expanding the U.S. Minimally Invasive Oncology Devices Market?

The largest structural driver is the absolute volume of U.S. cancer. More than 2 million new diagnoses annually create a substantial pipeline of patients requiring biopsy, staging, surgical removal, local tumor destruction, symptom management, recurrence treatment, and metastatic disease intervention. Prostate, breast, lung, colorectal, kidney, liver, uterine, pancreatic, and bladder cancers collectively support high procedural demand across surgical and interventional specialties.

A second driver is the continuing movement away from highly invasive surgery where less invasive approaches can achieve acceptable oncologic outcomes. The economic importance of this transition is considerable. Open cancer surgery can require substantial inpatient capacity, anesthesia time, postoperative nursing, pain management, wound care, and rehabilitation. Robotic, laparoscopic, percutaneous, endoscopic, and catheter-based technologies can reduce parts of this resource burden and improve hospital throughput.

A third major driver is the rapid expansion of robotic-assisted cancer surgery. Urology remains one of the strongest robotic specialties because prostatectomy, partial nephrectomy, nephrectomy, and cystectomy frequently involve complex anatomy in which enhanced visualization and instrument articulation can provide procedural advantages. Robotic penetration is also significant in gynecologic, colorectal, thoracic, and selected general oncology procedures.

The competitive intensity of robotic surgery is increasing. Intuitive’s da Vinci platform remains the leading installed robotic ecosystem, but U.S. entry of additional platforms is expanding purchasing choice. Medtronic’s Hugo robotic-assisted surgery system received U.S. clearance for urologic procedures in late 2025, including prostatectomy, nephrectomy, and cystectomy. Those procedure categories collectively represent approximately 230,000 U.S. surgeries annually according to the company, illustrating the scale of the addressable urologic workflow.

A fourth driver is the growth of interventional oncology. Image-guided ablation and embolization have evolved from niche procedural techniques into important components of multidisciplinary cancer treatment. Interventional radiologists increasingly treat primary and metastatic tumors through percutaneous ablation, radioembolization, chemoembolization, bland embolization, irreversible electroporation, cement augmentation, and other targeted procedures.

Local tumor treatment is particularly relevant for liver, kidney, lung, prostate, and selected bone lesions. It is also increasingly relevant when patients have limited metastatic disease, are poor candidates for major surgery, require repeat treatment, or need preservation of organ function. These factors expand the addressable patient pool beyond patients receiving curative surgery alone.

A fifth driver is the growing importance of focal therapy. Traditional cancer surgery often removes an entire organ or a substantial amount of normal tissue around the malignant lesion. Newer systems are increasingly designed around destroying only the tumor and an appropriate margin. Focal therapy is especially commercially important in prostate, renal, hepatic, and selected pulmonary tumors because preserving surrounding tissue may improve quality of life and expand treatment eligibility.

A sixth driver is favorable demographic pressure. Cancer incidence rises strongly with age, while the U.S. population aged 65 and older continues to expand. Older patients are also more likely to have cardiovascular, pulmonary, renal, or metabolic comorbidities that increase the risk associated with major surgery. This creates a clinically important population for percutaneous, robotic, endoluminal, and focal approaches capable of reducing operative trauma.

A seventh driver is hospital capacity economics. Cancer service lines compete for operating-room slots, inpatient beds, imaging resources, anesthesia coverage, nursing capacity, and specialized staff. Procedures that enable shorter admissions, faster room turnover, lower postoperative intensity, and scheduled outpatient treatment can create operational capacity without requiring equivalent expansion of hospital infrastructure.

Finally, reimbursement and evidence generation are becoming stronger determinants of adoption. Hospitals increasingly require manufacturers to provide procedure economics, coding information, reimbursement support, clinical evidence, comparative outcome data, training programs, and post-market utilization evidence. Products that enter the market without a clear economic pathway face slower adoption regardless of technical sophistication.

 

Innovation in Focus: How Manufacturers Are Raising the Clinical and Economic Bar?

Innovation is moving from simply reducing incision size toward eliminating the need for an incision in selected procedures. Percutaneous tumor destruction, endoluminal intervention, natural-orifice access, catheter-directed therapy, focused ultrasound, and histotripsy represent a broader evolution toward treatment without conventional surgical exposure.

Histotripsy is one of the most strategically significant emerging technologies. The FDA granted De Novo authorization to HistoSonics’ Edison System in 2023 for non-thermal mechanical tissue ablation. Unlike thermal technologies, histotripsy uses focused ultrasound energy to mechanically disrupt targeted tissue. The technology has created a new commercial category within non-invasive or minimally invasive tumor treatment and has attracted significant interest from major U.S. liver programs.

Irreversible electroporation is another important area. AngioDynamics received FDA clearance in December 2024 for the NanoKnife System for prostate tissue ablation following a pivotal study involving 121 patients at 17 clinical sites. The development expands the commercial position of non-thermal focal therapy in urologic oncology and illustrates how manufacturers are moving beyond generalized soft-tissue ablation toward cancer-site-specific clinical pathways.

High-intensity focused ultrasound is developing in parallel. EDAP’s Focal One platform targets prostate tissue using robotic HIFU, with additional FDA-cleared imaging and workflow enhancements introduced in 2025. The competitive direction in prostate cancer is therefore moving beyond robotic prostatectomy alone toward multiple minimally invasive pathways including robotic surgery, HIFU, irreversible electroporation, cryoablation, and other tissue-preserving approaches.

Robotic-assisted surgery itself is undergoing a second innovation cycle. The first phase centered on whether robotic surgery could be clinically adopted. The current phase centers on force sensing, operating-room integration, advanced imaging, data capture, computational assistance, instrument economics, workflow efficiency, and competition between platforms. Intuitive’s fifth-generation da Vinci 5 system received FDA clearance in 2024 and incorporates force-feedback capabilities, enhanced computing capacity, upgraded visualization, workflow integration, and new surgeon-interface technologies.

Endoluminal robotics creates another important opportunity, especially in lung oncology. Advanced robotic bronchoscopy and navigation platforms can improve access to peripheral pulmonary lesions, supporting biopsy and potentially creating future pathways linking detection directly with local treatment. Intuitive reported approximately 144,100 Ion procedures globally during 2025, up 51% from 2024, demonstrating the speed at which robotic endoluminal procedure ecosystems can scale.

Image integration is becoming equally important. Ablation success depends on tumor visualization, device placement, treatment-margin assessment, and confirmation of the treated zone. Manufacturers increasingly integrate CT, ultrasound, fluoroscopy, cone-beam CT, electromagnetic navigation, software planning, fusion imaging, and artificial intelligence into procedural workflows.

The commercial implication is significant: future winners may not be manufacturers of the most powerful ablation generator or most technically advanced surgical instrument in isolation. Competitive advantage will increasingly depend on controlling the workflow connecting imaging, navigation, access, therapy delivery, confirmation, documentation, and follow-up.

 

Segmentation Insights

The U.S. Minimally Invasive Oncology Devices Market is segmented on the basis of product category, application, end user, technology type, and region.

 

By Product Category

Robotic and Laparoscopic Oncology Surgical Devices

Robotic and advanced laparoscopic systems represent the largest value-intensive product category. The segment includes robotic surgical platforms, surgeon consoles, patient-side systems, robotic instruments, energy devices, staplers, laparoscopic visualization systems, trocars, insufflation products, vessel-sealing systems, and procedure-specific consumables.

Cancer surgery is attractive for robotic manufacturers because many procedures are technically demanding and generate recurring instrument utilization. Prostatectomy remains a central robotic oncology procedure, while partial nephrectomy, cystectomy, hysterectomy, colectomy, rectal surgery, thoracic resection, and selected head-and-neck procedures create additional revenue pools.

Capital competition will intensify during 2026–2035 as U.S. hospitals seek alternatives to single-platform dependence and evaluate total robotic-program economics rather than system price alone.

Tumor Ablation Devices

Tumor ablation is expected to be among the fastest-growing product categories. The segment includes microwave ablation systems, radiofrequency generators, cryoablation systems, HIFU platforms, irreversible electroporation systems, histotripsy platforms, electrodes, probes, applicators, needles, generators, cooling equipment, and treatment-planning accessories.

Growth is supported by increasing acceptance of focal treatment in liver, kidney, lung, prostate, and metastatic tumors. Ablation is commercially attractive because many platforms combine capital equipment with recurring single-use treatment devices.

Embolization and Radioembolization Devices

This segment includes embolic microspheres, Y-90 radioembolization products, delivery catheters, microcatheters, guidewires, access devices, vascular closure products, and related interventional oncology accessories.

Liver cancer represents the principal clinical market, although embolization is also used for metastatic hepatic disease and symptom management in selected tumors. Radioembolization continues to occupy a premium-value position because it combines device delivery with highly targeted intra-arterial radiation.

Endoscopic and Endoluminal Oncology Devices

Therapeutic endoscopy and endoluminal systems are becoming increasingly important as cancer diagnosis and intervention converge. The category includes therapeutic endoscopes, robotic bronchoscopy systems, endoscopic ultrasound devices, biopsy accessories, resection instruments, electrosurgical accessories, tumor-marking tools, stents, navigation equipment, and lesion-access technologies.

Growth is particularly important in lung, colorectal, esophageal, gastric, pancreatic, and biliary oncology. Improved access to peripheral lung lesions is creating one of the strongest growth opportunities as screening identifies smaller pulmonary nodules requiring tissue diagnosis.

Oncology Biopsy, Access, Navigation and Procedural Support Devices

This recurring-consumable category includes biopsy needles, coaxial systems, introducers, access sheaths, navigation systems, localization devices, tumor markers, fiducials, drainage products, procedural needles, and image-guided intervention accessories.

Its average selling price is lower than robotic or ablation systems, but procedure frequency is high. Precision oncology also increases the importance of obtaining adequate tissue for histology and molecular testing, supporting demand for reliable biopsy technologies.

 

By Application

Prostate and Urologic Oncology

Urologic oncology represents one of the strongest minimally invasive application segments. Approximately 313,780 prostate cancer cases were expected in the U.S. in 2025, while kidney and renal pelvis cancers contributed approximately 80,980 additional diagnoses.

Robotic prostatectomy, robotic partial nephrectomy, focal HIFU, cryoablation, irreversible electroporation, biopsy navigation, and minimally invasive cystectomy create a diversified device opportunity. The emerging competitive question is whether more intermediate-risk patients can be managed with focal treatment rather than whole-gland therapy or radical surgery.

Liver and Hepatobiliary Oncology

The liver represents one of the most technology-intensive interventional oncology markets. Treatment can include microwave ablation, radiofrequency ablation, irreversible electroporation, histotripsy, transarterial chemoembolization, bland embolization, and Y-90 radioembolization.

Commercial demand extends beyond primary hepatocellular carcinoma because colorectal, neuroendocrine, breast, and other cancers frequently metastasize to the liver. This increases the procedure opportunity beyond primary liver-cancer incidence alone.

Lung and Thoracic Oncology

Approximately 226,650 lung and bronchus cancers were expected in 2025, making lung oncology a major minimally invasive device opportunity. Advances in low-dose CT screening and peripheral-lesion detection are increasing demand for guided bronchoscopy, robotic bronchoscopy, biopsy systems, thoracoscopic surgery, robotic lung resection, ablation, and image-guided treatment.

The long-term commercial opportunity lies in connecting diagnosis and therapy. A platform capable of navigating to a small lesion, confirming malignancy, and eventually delivering local therapy through the same procedural ecosystem could materially change lung-cancer workflow economics.

Colorectal and Gastrointestinal Oncology

Approximately 154,270 colorectal cancers were expected in the United States in 2025. Minimally invasive treatment includes laparoscopic and robotic colectomy, rectal surgery, endoscopic mucosal and submucosal resection, lesion localization, liver-metastasis ablation, stenting, and image-guided intervention.

Growing colorectal cancer incidence among younger adults may also influence future procedure demand. GI oncology is strategically important because it links screening endoscopy, diagnostic biopsy, surgical intervention, therapeutic endoscopy, and management of metastatic liver disease.

Gynecologic and Other Solid Tumors

Minimally invasive devices are also widely used in uterine, cervical, ovarian, pancreatic, adrenal, bone, and selected breast oncology procedures. Gynecologic oncology remains an important robotic surgery application, while pancreatic and biliary cancer support therapeutic endoscopy and image-guided intervention. Bone metastasis management creates additional demand for ablation and stabilization technologies.

 

By End User

Hospitals and Integrated Health Systems

Hospitals account for the dominant revenue share because complex cancer surgery, robotic systems, interventional oncology, anesthesia-intensive ablation, radioembolization, and multidisciplinary oncology programs remain concentrated in acute-care facilities.

Large health systems increasingly negotiate enterprise contracts covering capital equipment, procedure consumables, training, service, digital integration, and volume commitments. Vendor standardization can therefore shift millions of dollars of purchasing across multiple facilities.

Comprehensive Cancer Centers and Academic Medical Centers

Academic cancer centers are disproportionately important to market development. They lead clinical trials, create procedural protocols, train specialists, evaluate emerging ablation systems, establish focal-therapy programs, and influence community adoption.

Novel technologies such as histotripsy, irreversible electroporation, robotic bronchoscopy, advanced focal therapy, and new robotic surgical platforms generally establish clinical credibility in these centers before moving into broader community practice.

Ambulatory Surgery Centers

ASCs represent a growing end-user opportunity for selected minimally invasive oncology procedures as reimbursement, anesthesia practice, patient selection, and procedural efficiency improve.

The largest opportunity is likely to involve lower-acuity urologic, endoscopic, biopsy, and selected surgical procedures rather than high-complexity liver embolization or major oncologic resection. Vendors targeting ASCs must provide compact systems, predictable disposable costs, rapid room turnover, and service models compatible with lower facility reimbursement.

Interventional Radiology Centers and Outpatient Procedure Facilities

Percutaneous biopsy and selected image-guided interventions are increasingly moving into specialized outpatient environments. Growth is strongest when procedures can be performed safely without substantial postoperative monitoring.

This shift favors portable ultrasound, compact ablation generators, simplified navigation, efficient access products, and disposable procedure kits. Outpatient interventional oncology could become a meaningful secondary growth channel over the next decade.

Specialty Urology, Gastroenterology, Pulmonology and Oncology Practices

Specialist practices are increasingly relevant as minimally invasive oncology becomes more procedural and decentralized. Urology groups can support prostate biopsy and focal treatment programs, gastroenterology practices participate in therapeutic endoscopy, and pulmonary groups increasingly perform advanced bronchoscopy.

Manufacturers entering these settings must address physician training, referral development, payer authorization, capital financing, procedural utilization, and service support rather than relying solely on hospital sales strategies.

 

By Technology Type

Robotic-Assisted and Computer-Assisted Intervention

Robotic technology currently represents the largest premium-value technology segment. Competition is expanding from robotic surgery into robotic bronchoscopy, endoluminal navigation, automated planning, and computational workflow support.

The economic model is attractive because it combines system placements with recurring instruments, accessories, service contracts, software, and training.

Thermal Ablation

Microwave, radiofrequency, and cryoablation represent established local tumor-treatment modalities. Microwave systems are gaining importance because of relatively rapid energy delivery and the ability to create larger ablation zones in selected tissues. Cryoablation retains advantages in cases where visualization of the treatment zone and preservation of adjacent anatomy are clinically important.

Non-Thermal and Focused-Energy Ablation

Irreversible electroporation, histotripsy, and HIFU represent high-growth technologies because they broaden the concept of tissue destruction beyond heat.

These platforms are particularly attractive where preservation of sensitive surrounding anatomy is important. Their commercial expansion will depend on longer-term oncologic evidence, reimbursement development, training, and treatment-center capacity.

Catheter-Based Transarterial Therapy

Catheter-directed oncology includes radioembolization, chemoembolization, bland embolization, and associated vascular access technologies. Liver tumors account for the majority of demand.

This category generates recurring device revenue and requires substantial procedural expertise, creating stronger barriers to entry than simple disposable-product markets.

Image-Guided and Endoluminal Navigation

Navigation is becoming an enabling technology rather than an optional accessory. Electromagnetic navigation, robotic bronchoscopy, ultrasound fusion, cone-beam CT guidance, treatment-planning software, and image-registration systems allow physicians to reach smaller or anatomically difficult tumors.

The segment is expected to gain strategic importance as minimally invasive treatment moves toward smaller lesions, earlier-stage disease, and highly focal intervention.

 

Regional Insights: Where the U.S. Market Is Expanding Fastest

The U.S. Minimally Invasive Oncology Devices Market is geographically segmented into the South, West, Northeast, and Midwest. Regional performance is determined by cancer incidence, population age, population growth, availability of comprehensive cancer programs, academic-center concentration, robotic surgery penetration, interventional radiology capacity, reimbursement mix, specialist availability, and hospital capital-investment intensity.

The South is estimated to represent the largest regional market in 2025 at approximately USD 4.35 billion, followed by the West at around USD 2.71 billion, the Northeast at approximately USD 2.54 billion, and the Midwest at around USD 2.20 billion.

South

The South represents the largest regional opportunity because it combines population scale, rapid migration, substantial cancer burden, large Medicare populations, expanding hospital infrastructure, and high-volume cancer centers.

Texas is one of the most strategically important state markets. The state had approximately 31.7 million residents in 2025 and an estimated 150,870 new cancer cases. Houston, Dallas-Fort Worth, Austin, and San Antonio support major cancer, urology, interventional radiology, thoracic surgery, and robotic-surgery programs. Texas also benefits from a large network of physician-owned and integrated specialty practices, creating opportunities outside tertiary hospitals.

Florida represents another critical market, with approximately 171,960 projected new cancer cases in 2025. The combination of more than 23 million residents and a high proportion of older adults creates substantial demand for prostate, lung, colorectal, kidney, and liver procedures. Florida is particularly attractive for technologies designed to reduce hospitalization among older and medically complex patients.

North Carolina recorded an estimated 71,320 new cancer cases in 2025 and has a strong academic and biotechnology ecosystem. Major referral centers support adoption of robotic surgery, advanced endoscopy, focal treatment, clinical trials, and interventional oncology.

Georgia, with approximately 66,210 projected cancer cases in 2025, is benefiting from population growth around Atlanta and expansion of regional health systems. Virginia, Tennessee, Maryland, South Carolina, Kentucky, Louisiana, Alabama, Oklahoma, Arkansas, Mississippi, and West Virginia add substantial procedural demand.

A notable characteristic of the South is its mixture of highly sophisticated urban cancer centers and large rural or underserved populations. This creates two different commercial strategies. High-value robotic and advanced ablation systems can be concentrated in regional referral hubs, while outpatient biopsy, navigation, endoscopy, and lower-complexity interventions can expand closer to patients.

The South is expected to remain the largest regional market through 2035. Expansion will be driven by population growth, increasing robotic competition, focal prostate therapy, liver intervention, growing lung-cancer diagnostic programs, and health-system investment in cancer service-line capacity.

West

The West is expected to record the fastest regional growth through 2035 because of its strong innovation ecosystem, technology adoption, medtech concentration, venture funding, major academic centers, and rapidly expanding populations in several states.

California is the single most important state market in the West and one of the largest nationally. Approximately 199,980 new cancer cases were projected for California in 2025. The state supports major oncology programs across Los Angeles, San Francisco, San Diego, Orange County, Sacramento, and Silicon Valley.

California is especially important for early adoption of robotic surgery, digital operating-room technologies, robotic bronchoscopy, image-guided intervention, focal prostate treatment, artificial-intelligence-supported navigation, and emerging tumor-ablation systems. Its concentration of technology companies and clinical research institutions creates close interaction between device development and clinical implementation.

Arizona, with approximately 42,560 projected new cancer cases in 2025, is increasingly important because of rapid population growth and an expanding older population. Phoenix and Scottsdale have developed strong specialty oncology, urology, and hospital infrastructure that supports minimally invasive cancer care.

Washington recorded approximately 46,500 projected new cancer cases in 2025 and has sophisticated academic and integrated-delivery-system environments. Colorado, Oregon, Nevada, Utah, Idaho, New Mexico, Montana, Wyoming, Alaska, and Hawaii provide additional market opportunities.

The region’s strongest competitive characteristic is its willingness to evaluate new technology when it can demonstrate measurable improvements in procedural workflow. Device developers frequently use Western U.S. academic and private health systems as early commercial reference centers.

The West is therefore expected to gain national share in advanced navigation, robotic bronchoscopy, non-thermal ablation, robotic surgery, focal therapy, and digitally connected procedural oncology.

Northeast

The Northeast remains one of the highest-value markets on a per-procedure basis because of its density of academic hospitals, NCI-designated cancer centers, specialist physicians, sophisticated tumor boards, and clinical-trial infrastructure.

New York is the dominant state market, with approximately 123,000 new cancer cases projected in 2025. New York City alone contains one of the world’s largest concentrations of high-acuity oncology programs, supporting advanced robotic surgery, interventional oncology, therapeutic endoscopy, lung navigation, focal treatment, and complex multidisciplinary care.

Pennsylvania, with approximately 90,240 projected new cancer cases, is another major device market. Philadelphia and Pittsburgh support advanced cancer surgery, interventional oncology, academic research, and high procedural volumes.

Massachusetts had approximately 44,000 projected new cancer cases in 2025 and is disproportionately important relative to its population because of its biomedical research ecosystem, academic hospitals, biotechnology companies, venture capital, and specialized cancer institutions. Novel devices can gain national clinical credibility when successfully adopted in Massachusetts-based academic programs.

New Jersey, Connecticut, Maine, Vermont, New Hampshire, Rhode Island, and Delaware complete the regional market. New Jersey benefits from dense population and proximity to New York and Philadelphia medical ecosystems, while Connecticut supports several sophisticated integrated systems.

Growth in the Northeast will likely be somewhat slower than in the West or South because the provider market is mature and population expansion is limited. However, average device value and procedural complexity are high. Manufacturers frequently prioritize this region for clinical evidence generation, physician education, new-product evaluation, and premium technology introduction.

Midwest

The Midwest is estimated at approximately USD 2.20 billion in 2025 and represents a durable market for robotic oncology surgery, interventional radiology, therapeutic endoscopy, cancer biopsy, and ablation.

Illinois is the region’s largest individual market, with approximately 78,870 projected new cancer cases in 2025. Chicago supports a large academic and community-provider ecosystem and is an important center for robotic surgery, GI oncology, thoracic procedures, and interventional care.

Ohio had approximately 77,010 projected cancer cases in 2025 and contains several nationally recognized health systems with strong cancer, urology, surgery, and interventional radiology programs.

Michigan, Minnesota, Wisconsin, Indiana, Missouri, Iowa, Kansas, Nebraska, North Dakota, and South Dakota provide the remainder of regional demand. Minnesota is strategically important because of its established medical-device industry and clinical-innovation infrastructure, while Michigan has a significant cancer population and large integrated delivery networks.

The Midwest is particularly sensitive to clinical economics and purchasing standardization. Hospitals frequently require clear evidence of procedure efficiency, predictable disposable cost, clinical training, and service reliability before adopting new capital equipment.

Rural geography also creates opportunities for technologies that reduce the need for patients to undergo major inpatient surgery. Regional referral centers can use focal intervention and image-guided treatment to centralize complex care while allowing patients to return more quickly to community-based follow-up.

The Midwest will likely remain the slowest-growing of the four regions, but its large procedure base, recognized health systems, stable specialist networks, and substantial cancer burden make it an important recurring-revenue market.

 

Key Market Players

The U.S. minimally invasive oncology devices competitive landscape is highly heterogeneous. No single manufacturer controls the entire market because robotic surgery, interventional oncology, therapeutic endoscopy, ablation, embolization, image guidance, and procedural access require different technologies and specialist relationships.

Some of the most relevant companies competing in or influencing the U.S. minimally invasive oncology ecosystem include Intuitive Surgical, Medtronic, Johnson & Johnson MedTech, Boston Scientific Corporation, Stryker Corporation, Olympus Corporation, Fujifilm Healthcare, KARL STORZ, Siemens Healthineers, GE HealthCare, Philips, Canon Medical Systems USA, AngioDynamics, HistoSonics, EDAP TMS, Profound Medical, IceCure Medical, Terumo, Merit Medical Systems, Sirtex Medical, Cook Medical, BD, Teleflex, and CONMED Corporation.

Intuitive Surgical maintains the strongest position in robotic-assisted soft-tissue surgery through its da Vinci ecosystem and is expanding the minimally invasive disease-management opportunity through Ion robotic bronchoscopy. The company reported approximately 3.15 million da Vinci procedures globally during 2025 and a da Vinci installed base exceeding 11,100 systems at year-end, illustrating the scale of its recurring instrument and service model.

Medtronic has become a more important U.S. robotic competitor following FDA clearance of Hugo for urologic surgery. Its broader surgical portfolio creates an opportunity to integrate robotic surgery with stapling, energy, visualization, electrosurgery, and digital operating-room products.

Johnson & Johnson MedTech maintains substantial exposure through Ethicon surgical technologies and the NEUWAVE microwave ablation portfolio. Boston Scientific occupies an important interventional oncology position through TheraSphere Y-90 radioembolization and a broader portfolio of interventional devices.

AngioDynamics is strategically important in focal and interventional oncology through NanoKnife irreversible electroporation. HistoSonics is establishing a new category around histotripsy. EDAP TMS competes in prostate focal therapy through Focal One HIFU, while Profound Medical is developing MRI-guided transurethral ultrasound treatment approaches.

Olympus, Fujifilm, and KARL STORZ remain relevant to endoscopic and laparoscopic oncology workflows. Siemens Healthineers, GE HealthCare, Philips, and Canon Medical influence the image-guidance environment underpinning percutaneous and interventional procedures.

Merit Medical, Terumo, Sirtex, Cook Medical, BD, Teleflex, and CONMED compete across embolization, vascular access, biopsy, energy, navigation, and procedural consumables.

Competitive differentiation through 2035 will increasingly depend on evidence rather than engineering specifications alone. Manufacturers able to demonstrate complete tumor treatment, reduced retreatment, lower complication rates, shorter procedure time, shorter hospitalization, preservation of organ function, and attractive reimbursement economics will have greater ability to defend premium pricing.

 

Recent Developments

The recent development cycle in the U.S. market demonstrates how quickly minimally invasive cancer care is moving beyond conventional laparoscopy.

In October 2023, the FDA granted De Novo authorization to the HistoSonics Edison System, establishing a regulatory pathway for focused-ultrasound-based non-thermal mechanical tissue ablation. The approval created one of the most significant new technology categories in interventional oncology and accelerated U.S. interest in incisionless tumor treatment.

In March 2024, Intuitive Surgical received FDA clearance for da Vinci 5, its fifth-generation robotic platform. The system introduced force-feedback technology, upgraded visualization and computing capabilities, and new workflow features, reinforcing competition around the entire digital operating-room ecosystem rather than robotic mechanics alone.

In December 2024, AngioDynamics received FDA clearance for the NanoKnife System for prostate tissue ablation. The clearance followed the PRESERVE clinical study involving 121 patients at 17 sites and broadened the commercial potential for irreversible electroporation within U.S. focal prostate treatment.

During 2025, focal prostate therapy continued to evolve. EDAP received FDA clearance for imaging and workflow enhancements to Focal One robotic HIFU, improving ultrasound visualization and treatment-planning functionality.

In December 2025, Medtronic received FDA clearance for the Hugo robotic-assisted surgery system for urologic procedures, including prostatectomy, nephrectomy, and cystectomy. Its U.S. entry introduces greater capital-platform competition in a robotic surgery market historically dominated by Intuitive and could influence contracting, system pricing, training models, and robotic-program expansion.

In February 2026, the FDA approved a TheraSphere PMA supplement specifying use of Boston Scientific’s Y-90 glass microspheres for local tumor control in selected patients with solitary unresectable hepatocellular carcinoma. The development reinforces radioembolization’s continuing role within minimally invasive liver oncology.

In March 2026, the FDA also cleared an updated NanoKnife Generator, demonstrating continued product iteration around irreversible electroporation as manufacturers attempt to expand focal-treatment workflows and improve procedural usability.

The broader development pattern is clear. U.S. oncology device innovation is shifting simultaneously toward robotics, image guidance, organ-preserving treatment, non-thermal ablation, targeted intra-arterial therapy, and increasingly precise lesion access.

 

Conclusion

The U.S. Minimally Invasive Oncology Devices Market Size & Share is positioned to expand from approximately USD 11.80 billion in 2025 to USD 38.15 billion by 2035, representing a 12.45% CAGR during 2026–2035.

The market’s growth is supported by the combination of more than 2 million new cancer diagnoses annually, a growing cancer-survivor population, aging demographics, increased detection of treatable localized lesions, expansion of robotic surgery, increasing use of interventional oncology, and hospital pressure to lower the clinical and economic burden of major surgery.

The most important commercial change during the forecast period will be movement from conventional minimally invasive surgery toward precision intervention. Value creation will increasingly concentrate in technologies capable of locating a tumor accurately, navigating to it through the least traumatic route, selectively destroying or removing malignant tissue, preserving surrounding anatomy, confirming treatment completeness, and returning the patient to normal activity more rapidly.

Robotic-assisted surgery will remain the largest premium platform opportunity, but some of the highest growth rates are expected in robotic bronchoscopy, focal prostate therapy, microwave ablation, non-thermal irreversible electroporation, histotripsy, image-guided navigation, radioembolization, and other organ-preserving technologies.

Hospital purchasing behavior will be equally important. Health systems will increasingly compare technologies based on total episode economics rather than device price. Manufacturers that can reduce operating-room occupancy, inpatient days, anesthesia intensity, complication costs, repeat procedures, and clinician workload will possess greater leverage in value-analysis discussions.

Regionally, the South will remain the largest opportunity because of population scale and cancer burden, while the West should generate some of the strongest innovation-led growth. The Northeast will remain central to high-acuity adoption and clinical evidence generation, and the Midwest will provide a large, stable procedural market where clinical and economic justification strongly influences purchasing.

At the state level, California, Florida, Texas, New York, Pennsylvania, Illinois, Ohio, North Carolina, Georgia, Massachusetts, Washington, and Arizona will remain particularly important because they combine significant cancer populations with high-capability hospital systems and specialist infrastructure.

For manufacturers, investors, distributors, hospital executives, and strategy teams, the central market question through 2035 will not simply be whether minimally invasive oncology expands. The more important questions concern which cancer procedures transition away from open surgery, which focal technologies achieve sufficient oncologic evidence to become routine care, which procedures migrate toward outpatient settings, how robotic competition changes hospital contracting, and which vendors can own the complete image-guided oncology workflow rather than a single procedural device.

The companies best positioned to capture the next decade of market expansion will therefore be those capable of combining clinical differentiation, specialist training, recurring consumables, image integration, reimbursement support, workflow efficiency, real-world outcomes, and credible long-term evidence into a unified minimally invasive oncology platform.

 

TABLE OF CONTENT

1. U.S. Minimally Invasive Oncology Devices Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Analytical Frameworks & Forecasting Models
1.3.6. Data Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Minimally Invasive Oncology Device Manufacturers
1.6.2. Component, Energy-System and Contract Manufacturing Suppliers
1.6.3. Hospitals and Integrated Delivery Networks
1.6.4. Comprehensive Cancer Centers and Academic Medical Centers
1.6.5. Interventional Radiology, Urology, Gastroenterology and Pulmonology Practices
1.6.6. Ambulatory Surgery Centers and Outpatient Procedure Facilities
1.6.7. Group Purchasing Organizations, Distributors and Specialty Suppliers
1.6.8. Payers, Regulators and Clinical Decision-Makers

What this section provides: This section defines the market boundary, study scope, methodology, assumptions, device ecosystem, and stakeholder landscape so clients understand how the U.S. minimally invasive oncology devices market is measured, segmented, and validated.

2. U.S. Minimally Invasive Oncology Devices Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. High-Growth Opportunity Areas
2.8. Leading Minimally Invasive Oncology Procedure Trends
2.9. Strategic Investment Hotspots

What this section provides: This section gives decision-makers a concise view of market size, growth trajectory, key procedural demand pockets, technology adoption, competitive intensity, and high-priority investment opportunities through 2035.

3. U.S. Minimally Invasive Oncology Devices Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Rising U.S. Cancer Incidence and Expanding Treatment Population
3.1.2. Shift from Open Cancer Surgery Toward Minimally Invasive Intervention
3.1.3. Expansion of Robotic-Assisted Oncology Surgery
3.1.4. Growth of Image-Guided Interventional Oncology Procedures
3.1.5. Increasing Adoption of Focal and Organ-Preserving Cancer Therapies
3.1.6. Aging Population and Demand for Lower-Morbidity Procedures
3.1.7. Hospital Focus on Length-of-Stay Reduction and Procedure Throughput
3.2. Restraints and Their Impact Analysis
3.2.1. High Capital Cost of Robotic and Advanced Ablation Platforms
3.2.2. Reimbursement Variability Across Emerging Focal Therapies
3.2.3. Limited Long-Term Oncologic Evidence for Selected New Technologies
3.2.4. Specialist Training and Procedural Learning-Curve Requirements
3.2.5. High Disposable and Procedure-Specific Consumable Costs
3.3. Opportunities and Their Impact Analysis
3.3.1. Histotripsy and Non-Thermal Tumor Ablation Expansion
3.3.2. Focal Prostate Cancer Treatment
3.3.3. Robotic Bronchoscopy and Peripheral Lung Lesion Intervention
3.3.4. Minimally Invasive Liver Tumor Treatment
3.3.5. Outpatient and Ambulatory Oncology Procedures
3.3.6. Image-Guided Navigation and AI-Assisted Intervention
3.3.7. Metastasis-Directed Local Therapy
3.4. Challenges and Their Impact Analysis
3.4.1. Comparative Clinical Evidence Requirements
3.4.2. Patient Selection Complexity
3.4.3. Hospital Capital Budget Constraints
3.4.4. Multidisciplinary Workflow Coordination
3.4.5. Physician Training and Credentialing Barriers
3.5. Patent & Innovation Analysis, 2021–2025
3.6. Clinical Workflow Economics Analysis
3.7. Hospital Capital Procurement Behavior Analysis
3.8. Oncology Procedure Migration from Inpatient to Outpatient Settings

What this section provides: This section explains the clinical, commercial, reimbursement, technological, and operational forces influencing market demand and helps clients assess growth opportunities, adoption barriers, and execution risk.

4. U.S. Minimally Invasive Oncology Devices Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry
4.3. Pricing Trend Analysis by Region, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.5. Impact of Digitalization, Robotics and Precision Oncology
4.6. Application & Innovation Landscape
4.7. FDA Regulatory Framework Analysis
4.8. CMS Reimbursement and Coverage Landscape
4.9. Import/Export Restrictions & Tariff Impact
4.10. Government Cancer Initiatives and Public Health Programs
4.11. Impact of Escalating Geopolitical Tensions
4.12. Hospital Value Analysis Committee Decision Framework
4.13. Capital Equipment versus Recurring Consumables Revenue Model
4.14. Clinical Evidence and Health Economic Requirements for New Technology Adoption

What this section provides: This section provides a complete view of the external market environment, including regulation, reimbursement, pricing, supply chain, technology adoption, clinical evidence requirements, and hospital procurement dynamics.

5. U.S. Minimally Invasive Oncology Devices Market – By Product Category

5.1. Overview
5.1.1. Segment Share Analysis, By Product Category, 2025 & 2035 (%)
5.1.2. Robotic and Laparoscopic Oncology Surgical Devices
5.1.2.1. Robotic Surgical Systems
5.1.2.2. Robotic Instruments and Accessories
5.1.2.3. Laparoscopic Visualization Systems
5.1.2.4. Energy and Vessel-Sealing Devices
5.1.2.5. Trocars, Staplers and Access Devices
5.1.3. Tumor Ablation Devices
5.1.3.1. Microwave Ablation Systems
5.1.3.2. Radiofrequency Ablation Systems
5.1.3.3. Cryoablation Systems
5.1.3.4. High-Intensity Focused Ultrasound Systems
5.1.3.5. Irreversible Electroporation Systems
5.1.3.6. Histotripsy Systems
5.1.4. Embolization and Radioembolization Devices
5.1.4.1. Radioembolization Devices
5.1.4.2. Embolic Microspheres and Particles
5.1.4.3. Microcatheters and Delivery Systems
5.1.4.4. Guidewires and Vascular Access Devices
5.1.5. Endoscopic and Endoluminal Oncology Devices
5.1.5.1. Therapeutic Endoscopy Systems
5.1.5.2. Robotic Bronchoscopy Systems
5.1.5.3. Endoscopic Ultrasound Devices
5.1.5.4. Tumor Resection and Electrosurgical Accessories
5.1.5.5. Endoluminal Stents and Access Devices
5.1.6. Oncology Biopsy, Access, Navigation and Procedural Support Devices
5.1.6.1. Biopsy Needles and Systems
5.1.6.2. Coaxial and Introducer Systems
5.1.6.3. Image-Guided Navigation Systems
5.1.6.4. Tumor Localization and Fiducial Devices
5.1.6.5. Procedural Access and Support Devices

What this section provides: This section identifies the product categories generating the largest revenue pools and evaluates which robotic, ablation, embolization, endoscopic, navigation, and recurring consumable categories are positioned for the strongest growth through 2035.

6. U.S. Minimally Invasive Oncology Devices Market – By Application

6.1. Overview
6.1.1. Segment Share Analysis, By Application, 2025 & 2035 (%)
6.1.2. Prostate and Urologic Oncology
6.1.2.1. Prostate Cancer
6.1.2.2. Kidney and Renal Cancer
6.1.2.3. Bladder Cancer
6.1.2.4. Other Urologic Malignancies
6.1.3. Liver and Hepatobiliary Oncology
6.1.3.1. Hepatocellular Carcinoma
6.1.3.2. Liver Metastases
6.1.3.3. Biliary and Hepatobiliary Malignancies
6.1.4. Lung and Thoracic Oncology
6.1.4.1. Primary Lung Cancer
6.1.4.2. Pulmonary Metastases
6.1.4.3. Mediastinal and Other Thoracic Tumors
6.1.5. Colorectal and Gastrointestinal Oncology
6.1.5.1. Colorectal Cancer
6.1.5.2. Gastric and Esophageal Cancer
6.1.5.3. Pancreatic Cancer
6.1.5.4. Gastrointestinal Metastatic Disease
6.1.6. Gynecologic and Other Solid Tumors
6.1.6.1. Uterine and Endometrial Cancer
6.1.6.2. Cervical Cancer
6.1.6.3. Ovarian Cancer
6.1.6.4. Bone and Soft-Tissue Tumors
6.1.6.5. Other Solid Tumors

What this section provides: This section helps clients understand minimally invasive device demand by cancer type and identify clinical applications with strong procedural volumes, focal-treatment potential, reimbursement relevance, and technology innovation.

7. U.S. Minimally Invasive Oncology Devices Market – By End User

7.1. Overview
7.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
7.1.2. Hospitals and Integrated Health Systems
7.1.3. Comprehensive Cancer Centers and Academic Medical Centers
7.1.4. Ambulatory Surgery Centers
7.1.5. Interventional Radiology Centers and Outpatient Procedure Facilities
7.1.6. Specialty Urology, Gastroenterology, Pulmonology and Oncology Practices

What this section provides: This section explains which care settings and customer groups are expected to drive capital purchasing, procedure adoption, disposable utilization, clinical innovation, and migration of selected oncology procedures toward outpatient care.

8. U.S. Minimally Invasive Oncology Devices Market – By Technology Type

8.1. Overview
8.1.1. Segment Share Analysis, By Technology Type, 2025 & 2035 (%)
8.1.2. Robotic-Assisted and Computer-Assisted Intervention
8.1.3. Thermal Ablation Technologies
8.1.3.1. Microwave Ablation
8.1.3.2. Radiofrequency Ablation
8.1.3.3. Cryoablation
8.1.4. Non-Thermal and Focused-Energy Ablation
8.1.4.1. Irreversible Electroporation
8.1.4.2. Histotripsy
8.1.4.3. High-Intensity Focused Ultrasound
8.1.5. Catheter-Based Transarterial Therapy
8.1.5.1. Radioembolization
8.1.5.2. Chemoembolization
8.1.5.3. Bland Embolization
8.1.6. Image-Guided and Endoluminal Navigation
8.1.6.1. Robotic Bronchoscopy
8.1.6.2. Electromagnetic Navigation
8.1.6.3. Image Fusion and Registration
8.1.6.4. AI-Assisted Procedural Planning and Navigation

What this section provides: This section evaluates the technology platforms transforming minimally invasive cancer treatment, including robotics, thermal and non-thermal ablation, catheter-directed intervention, image guidance, and navigation-enabled oncology workflows.

9. U.S. Minimally Invasive Oncology Devices Market – By Procurement Channel

9.1. Overview
9.1.1. Segment Share Analysis, By Procurement Channel, 2025 & 2035 (%)
9.1.2. Direct Hospital and Cancer Center Procurement
9.1.3. Integrated Delivery Network Enterprise Contracts
9.1.4. Group Purchasing Organization Contracts
9.1.5. Distributor and Specialty Supplier Sales
9.1.6. Ambulatory, Outpatient and Specialty Practice Procurement

What this section provides: This section helps clients understand how minimally invasive oncology devices are purchased across U.S. hospitals, cancer centers, IDNs, GPOs, distributors, ambulatory facilities, and specialty practices.

10. U.S. Minimally Invasive Oncology Devices Market – By Geography

10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
10.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
10.1.3. Regional Cancer Procedure Volume and Hospital Infrastructure Analysis
10.1.4. Regional Cancer Burden and Patient Demographics Analysis
10.1.5. Regional Reimbursement and Procurement Dynamics
10.1.6. Regional Robotic Surgery and Interventional Oncology Adoption Analysis

10.2. West Region

10.2.1. Regional Overview & Trends
10.2.2. West Region Minimally Invasive Oncology Device Key Manufacturers and Procurement Ecosystem
10.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.2.4. West Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.5. West Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.6. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.7. West Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.8. West Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.9. California

10.2.9.1. Overview
10.2.9.2. California Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.9.3. California Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.9.4. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.9.5. California Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.9.6. California Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.10. Washington

10.2.10.1. Overview
10.2.10.2. Washington Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.10.3. Washington Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.10.4. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.10.5. Washington Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.10.6. Washington Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.11. Arizona

10.2.11.1. Overview
10.2.11.2. Arizona Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.11.3. Arizona Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.11.4. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.11.5. Arizona Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.11.6. Arizona Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.12. Colorado

10.2.12.1. Overview
10.2.12.2. Colorado Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.12.3. Colorado Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.12.4. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.12.5. Colorado Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.12.6. Colorado Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.13. Oregon

10.2.13.1. Overview
10.2.13.2. Oregon Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.13.3. Oregon Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.13.4. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.13.5. Oregon Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.13.6. Oregon Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.14. Utah

10.2.14.1. Overview
10.2.14.2. Utah Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.14.3. Utah Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.14.4. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.14.5. Utah Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.14.6. Utah Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.15. Nevada

10.2.15.1. Overview
10.2.15.2. Nevada Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.15.3. Nevada Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.15.4. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.15.5. Nevada Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.15.6. Nevada Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.16. New Mexico

10.2.16.1. Overview
10.2.16.2. New Mexico Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.16.3. New Mexico Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.16.4. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.16.5. New Mexico Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.16.6. New Mexico Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.17. Idaho

10.2.17.1. Overview
10.2.17.2. Idaho Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.17.3. Idaho Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.17.4. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.17.5. Idaho Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.17.6. Idaho Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.18. Montana

10.2.18.1. Overview
10.2.18.2. Montana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.18.3. Montana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.18.4. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.18.5. Montana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.18.6. Montana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.19. Wyoming

10.2.19.1. Overview
10.2.19.2. Wyoming Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.19.3. Wyoming Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.19.4. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.19.5. Wyoming Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.19.6. Wyoming Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.20. Alaska

10.2.20.1. Overview
10.2.20.2. Alaska Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.20.3. Alaska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.20.4. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.20.5. Alaska Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.20.6. Alaska Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.21. Hawaii

10.2.21.1. Overview
10.2.21.2. Hawaii Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.21.3. Hawaii Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.21.4. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.21.5. Hawaii Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.21.6. Hawaii Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3. Northeast Region

10.3.1. Regional Overview & Trends
10.3.2. Northeast Region Minimally Invasive Oncology Device Key Manufacturers and Procurement Ecosystem
10.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.3.4. Northeast Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.5. Northeast Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.6. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.7. Northeast Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.8. Northeast Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.9. New York

10.3.9.1. Overview
10.3.9.2. New York Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.9.3. New York Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.9.4. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.9.5. New York Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.9.6. New York Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.10. Massachusetts

10.3.10.1. Overview
10.3.10.2. Massachusetts Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.10.3. Massachusetts Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.10.4. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.10.5. Massachusetts Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.10.6. Massachusetts Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.11. New Jersey

10.3.11.1. Overview
10.3.11.2. New Jersey Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.11.3. New Jersey Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.11.4. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.11.5. New Jersey Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.11.6. New Jersey Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.12. Pennsylvania

10.3.12.1. Overview
10.3.12.2. Pennsylvania Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.12.3. Pennsylvania Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.12.4. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.12.5. Pennsylvania Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.12.6. Pennsylvania Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.13. Connecticut

10.3.13.1. Overview
10.3.13.2. Connecticut Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.13.3. Connecticut Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.13.4. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.13.5. Connecticut Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.13.6. Connecticut Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.14. Maine

10.3.14.1. Overview
10.3.14.2. Maine Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.14.3. Maine Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.14.4. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.14.5. Maine Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.14.6. Maine Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.15. Vermont

10.3.15.1. Overview
10.3.15.2. Vermont Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.15.3. Vermont Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.15.4. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.15.5. Vermont Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.15.6. Vermont Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.16. New Hampshire

10.3.16.1. Overview
10.3.16.2. New Hampshire Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.16.3. New Hampshire Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.16.4. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.16.5. New Hampshire Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.16.6. New Hampshire Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.17. Rhode Island

10.3.17.1. Overview
10.3.17.2. Rhode Island Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.17.3. Rhode Island Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.17.4. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.17.5. Rhode Island Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.17.6. Rhode Island Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.18. Delaware

10.3.18.1. Overview
10.3.18.2. Delaware Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.18.3. Delaware Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.18.4. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.18.5. Delaware Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.18.6. Delaware Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4. South Region

10.4.1. Regional Overview & Trends
10.4.2. South Region Minimally Invasive Oncology Device Key Manufacturers and Procurement Ecosystem
10.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.4.4. South Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.5. South Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.6. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.7. South Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.8. South Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.9. Texas

10.4.9.1. Overview
10.4.9.2. Texas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.9.3. Texas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.9.4. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.9.5. Texas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.9.6. Texas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.10. Florida

10.4.10.1. Overview
10.4.10.2. Florida Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.10.3. Florida Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.10.4. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.10.5. Florida Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.10.6. Florida Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.11. Georgia

10.4.11.1. Overview
10.4.11.2. Georgia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.11.3. Georgia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.11.4. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.11.5. Georgia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.11.6. Georgia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.12. North Carolina

10.4.12.1. Overview
10.4.12.2. North Carolina Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.12.3. North Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.12.4. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.12.5. North Carolina Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.12.6. North Carolina Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.13. Tennessee

10.4.13.1. Overview
10.4.13.2. Tennessee Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.13.3. Tennessee Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.13.4. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.13.5. Tennessee Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.13.6. Tennessee Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.14. South Carolina

10.4.14.1. Overview
10.4.14.2. South Carolina Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.14.3. South Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.14.4. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.14.5. South Carolina Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.14.6. South Carolina Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.15. Alabama

10.4.15.1. Overview
10.4.15.2. Alabama Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.15.3. Alabama Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.15.4. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.15.5. Alabama Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.15.6. Alabama Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.16. Mississippi

10.4.16.1. Overview
10.4.16.2. Mississippi Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.16.3. Mississippi Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.16.4. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.16.5. Mississippi Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.16.6. Mississippi Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.17. Louisiana

10.4.17.1. Overview
10.4.17.2. Louisiana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.17.3. Louisiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.17.4. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.17.5. Louisiana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.17.6. Louisiana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.18. Arkansas

10.4.18.1. Overview
10.4.18.2. Arkansas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.18.3. Arkansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.18.4. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.18.5. Arkansas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.18.6. Arkansas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.19. Kentucky

10.4.19.1. Overview
10.4.19.2. Kentucky Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.19.3. Kentucky Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.19.4. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.19.5. Kentucky Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.19.6. Kentucky Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.20. Oklahoma

10.4.20.1. Overview
10.4.20.2. Oklahoma Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.20.3. Oklahoma Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.20.4. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.20.5. Oklahoma Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.20.6. Oklahoma Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.21. Virginia

10.4.21.1. Overview
10.4.21.2. Virginia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.21.3. Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.21.4. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.21.5. Virginia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.21.6. Virginia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.22. Maryland

10.4.22.1. Overview
10.4.22.2. Maryland Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.22.3. Maryland Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.22.4. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.22.5. Maryland Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.22.6. Maryland Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.23. West Virginia

10.4.23.1. Overview
10.4.23.2. West Virginia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.23.3. West Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.23.4. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.23.5. West Virginia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.23.6. West Virginia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5. Midwest Region

10.5.1. Regional Overview & Trends
10.5.2. Midwest Region Minimally Invasive Oncology Device Key Manufacturers and Procurement Ecosystem
10.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.5.4. Midwest Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.5. Midwest Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.6. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.7. Midwest Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.8. Midwest Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.9. Illinois

10.5.9.1. Overview
10.5.9.2. Illinois Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.9.3. Illinois Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.9.4. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.9.5. Illinois Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.9.6. Illinois Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.10. Ohio

10.5.10.1. Overview
10.5.10.2. Ohio Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.10.3. Ohio Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.10.4. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.10.5. Ohio Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.10.6. Ohio Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.11. Michigan

10.5.11.1. Overview
10.5.11.2. Michigan Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.11.3. Michigan Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.11.4. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.11.5. Michigan Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.11.6. Michigan Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.12. Minnesota

10.5.12.1. Overview
10.5.12.2. Minnesota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.12.3. Minnesota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.12.4. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.12.5. Minnesota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.12.6. Minnesota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.13. Indiana

10.5.13.1. Overview
10.5.13.2. Indiana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.13.3. Indiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.13.4. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.13.5. Indiana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.13.6. Indiana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.14. Wisconsin

10.5.14.1. Overview
10.5.14.2. Wisconsin Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.14.3. Wisconsin Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.14.4. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.14.5. Wisconsin Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.14.6. Wisconsin Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.15. Missouri

10.5.15.1. Overview
10.5.15.2. Missouri Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.15.3. Missouri Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.15.4. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.15.5. Missouri Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.15.6. Missouri Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.16. Iowa

10.5.16.1. Overview
10.5.16.2. Iowa Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.16.3. Iowa Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.16.4. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.16.5. Iowa Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.16.6. Iowa Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.17. Kansas

10.5.17.1. Overview
10.5.17.2. Kansas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.17.3. Kansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.17.4. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.17.5. Kansas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.17.6. Kansas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.18. Nebraska

10.5.18.1. Overview
10.5.18.2. Nebraska Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.18.3. Nebraska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.18.4. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.18.5. Nebraska Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.18.6. Nebraska Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.19. North Dakota

10.5.19.1. Overview
10.5.19.2. North Dakota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.19.3. North Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.19.4. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.19.5. North Dakota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.19.6. North Dakota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.20. South Dakota

10.5.20.1. Overview
10.5.20.2. South Dakota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.20.3. South Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.20.4. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.20.5. South Dakota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.20.6. South Dakota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

What this section provides: This section delivers detailed regional and state-level analysis across all 50 states, helping clients identify cancer-procedure hubs, robotic and interventional oncology adoption hotspots, hospital infrastructure concentration, procurement patterns, and state-level commercial opportunities.

11. U.S. Minimally Invasive Oncology Devices Market: Competitive Landscape & Company Profiles

11.1. Market Share Analysis, 2025
11.2. Company Positioning Matrix
11.2.1. Leaders
11.2.2. Challengers
11.2.3. Innovators
11.2.4. Emerging Players
11.3. Company Profiles
11.3.1. Intuitive Surgical, Inc.
11.3.2. Medtronic plc
11.3.3. Johnson & Johnson MedTech
11.3.4. Boston Scientific Corporation
11.3.5. Stryker Corporation
11.3.6. Olympus Corporation
11.3.7. FUJIFILM Healthcare
11.3.8. KARL STORZ SE & Co. KG
11.3.9. Siemens Healthineers
11.3.10. GE HealthCare
11.3.11. Philips
11.3.12. Canon Medical Systems USA
11.3.13. AngioDynamics, Inc.
11.3.14. HistoSonics, Inc.
11.3.15. EDAP TMS S.A.
11.3.16. Profound Medical Corp.
11.3.17. IceCure Medical Ltd.
11.3.18. Terumo Corporation
11.3.19. Merit Medical Systems, Inc.
11.3.20. Sirtex Medical
11.3.21. Cook Medical
11.3.22. BD
11.3.23. Teleflex Incorporated
11.3.24. CONMED Corporation

Note: Each company profile will include company overview, minimally invasive oncology device portfolio, U.S. market strategy, financial positioning, technology pipeline, clinical evidence, regulatory updates, partnerships, acquisitions, commercialization strategy, and recent developments.

What this section provides: This section gives clients competitor benchmarking, market-share visibility, portfolio positioning, innovation direction, commercialization strategies, and strategic intelligence on major minimally invasive oncology device manufacturers.

12. U.S. Minimally Invasive Oncology Devices Market: Future Market Outlook, 2026–2035

12.1. Scenario Analysis
12.1.1. Optimistic Scenario
12.1.2. Realistic Scenario
12.1.3. Pessimistic Scenario
12.2. Disruptive Technologies Impact
12.2.1. Histotripsy and Incisionless Tumor Destruction
12.2.2. Next-Generation Robotic Oncology Surgery Platforms
12.2.3. Irreversible Electroporation and Focal Cancer Therapy
12.2.4. Robotic Bronchoscopy and Endoluminal Intervention
12.2.5. AI-Assisted Image Guidance and Procedural Navigation
12.2.6. Advanced Microwave and Cryoablation Platforms
12.2.7. Personalized and Image-Guided Radioembolization
12.3. Emerging Business Trends
12.3.1. Shift Toward Organ-Preserving Oncology Treatment
12.3.2. Transition of Selected Procedures to Outpatient Settings
12.3.3. Platform-Based Hospital Contracting
12.3.4. Recurring Consumables and Procedure-Based Revenue Models
12.3.5. Integration of Imaging, Navigation and Therapy Delivery
12.4. Business Opportunities for Startups and Existing Players
12.5. Investment Prioritization Matrix
12.6. Procedure Migration Opportunity Matrix
12.7. Emerging Technology Adoption Timeline, 2026–2035

What this section provides: This section prepares clients for future technology shifts, procedure migration, market-structure changes, emerging treatment modalities, investment opportunities, and adoption scenarios through 2035.

13. U.S. Minimally Invasive Oncology Devices Market: Strategic Recommendations

13.1. Recommendations for Device Manufacturers
13.2. Recommendations for Hospitals and Integrated Health Systems
13.3. Recommendations for Comprehensive Cancer Centers
13.4. Recommendations for Investors and Private Equity Firms
13.5. Recommendations for Distributors and Channel Partners
13.6. Recommendations for New Entrants and Startups
13.7. Go-to-Market Strategy Considerations
13.8. Product Positioning and Portfolio Expansion Guidance
13.9. Clinical Evidence Generation Strategy
13.10. Reimbursement and Market Access Strategy
13.11. U.S. State-Level Commercial Prioritization Strategy
13.12. Partnership, Licensing and M&A Opportunity Framework

What this section provides: This section converts market intelligence into actionable recommendations for growth planning, product development, clinical evidence, commercialization, market access, state-level expansion, investment decisions, and competitive differentiation.

14. U.S. Minimally Invasive Oncology Devices Market: Disclaimer

14.1. Scope Limitation
14.2. Data Use Limitation
14.3. Forecasting Limitation
14.4. Legal Disclaimer
14.5. Third-Party Data Disclaimer

What this section provides: This section clarifies the report’s scope limitations, forecasting assumptions, legal boundaries, third-party information considerations, and permitted interpretation of market estimates.

 

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. Minimally Invasive Oncology Devices Market: Market Definition and Scope
TABLE 3: U.S. Minimally Invasive Oncology Devices Market: Research Methodology Framework
TABLE 4: U.S. Minimally Invasive Oncology Devices Market: Key Assumptions
TABLE 5: U.S. Minimally Invasive Oncology Devices Market: Market Ecosystem Overview
TABLE 6: U.S. Minimally Invasive Oncology Devices Market: Stakeholder Analysis
TABLE 7: U.S. Minimally Invasive Oncology Devices Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. Minimally Invasive Oncology Devices Market: Analyst Viewpoint Summary
TABLE 9: U.S. Minimally Invasive Oncology Devices Market: Market Attractiveness Index
TABLE 10: U.S. Minimally Invasive Oncology Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. Minimally Invasive Oncology Devices Market: Base Year Market Positioning, 2025
TABLE 12: U.S. Minimally Invasive Oncology Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 13: U.S. Minimally Invasive Oncology Devices Market: High-Growth Opportunity Areas
TABLE 14: U.S. Minimally Invasive Oncology Devices Market: Drivers; Impact Analysis
TABLE 15: U.S. Minimally Invasive Oncology Devices Market: Restraints; Impact Analysis
TABLE 16: U.S. Minimally Invasive Oncology Devices Market: Opportunities; Impact Analysis
TABLE 17: U.S. Minimally Invasive Oncology Devices Market: Challenges; Impact Analysis
TABLE 18: U.S. Minimally Invasive Oncology Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 19: U.S. Minimally Invasive Oncology Devices Market: Clinical Workflow Economics Matrix
TABLE 20: U.S. Minimally Invasive Oncology Devices Market: Hospital Capital Procurement Behavior Matrix
TABLE 21: U.S. Minimally Invasive Oncology Devices Market: Oncology Procedure Migration to Outpatient Settings
TABLE 22: U.S. Minimally Invasive Oncology Devices Market: PESTEL Analysis
TABLE 23: U.S. Minimally Invasive Oncology Devices Market: Porter’s Five Forces Analysis
TABLE 24: U.S. Minimally Invasive Oncology Devices Market: Pricing Trend Analysis by Region, 2025–2035
TABLE 25: U.S. Minimally Invasive Oncology Devices Market: Value Chain Analysis
TABLE 26: U.S. Minimally Invasive Oncology Devices Market: Supply Chain Analysis
TABLE 27: U.S. Minimally Invasive Oncology Devices Market: Digitalization, Robotics and Precision Oncology Impact
TABLE 28: U.S. Minimally Invasive Oncology Devices Market: Application & Innovation Landscape
TABLE 29: U.S. Minimally Invasive Oncology Devices Market: FDA Regulatory Framework Analysis
TABLE 30: U.S. Minimally Invasive Oncology Devices Market: CMS Reimbursement and Coverage Landscape
TABLE 31: U.S. Minimally Invasive Oncology Devices Market: Import/Export Restrictions & Tariff Impact
TABLE 32: U.S. Minimally Invasive Oncology Devices Market: Government Cancer Initiatives and Public Health Programs
TABLE 33: U.S. Minimally Invasive Oncology Devices Market: Impact of Escalating Geopolitical Tensions
TABLE 34: U.S. Minimally Invasive Oncology Devices Market: Hospital Value Analysis Committee Decision Framework
TABLE 35: U.S. Minimally Invasive Oncology Devices Market: Capital Equipment versus Recurring Consumables Revenue Model
TABLE 36: U.S. Minimally Invasive Oncology Devices Market: Clinical Evidence and Health Economic Requirements
TABLE 37: U.S. Minimally Invasive Oncology Devices Market: Product Category Snapshot, 2025
TABLE 38: Segment Dashboard; Definition and Scope, by Product Category
TABLE 39: U.S. Minimally Invasive Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 40: U.S. Minimally Invasive Oncology Devices Market: Segment Share Analysis, by Product Category, 2025 & 2035 (%)
TABLE 41: Robotic and Laparoscopic Oncology Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 42: Tumor Ablation Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 43: Embolization and Radioembolization Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 44: Endoscopic and Endoluminal Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 45: Oncology Biopsy, Access, Navigation and Procedural Support Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 46: U.S. Minimally Invasive Oncology Devices Market: Application Snapshot, 2025
TABLE 47: Segment Dashboard; Definition and Scope, by Application
TABLE 48: U.S. Minimally Invasive Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 49: U.S. Minimally Invasive Oncology Devices Market: Segment Share Analysis, by Application, 2025 & 2035 (%)
TABLE 50: Prostate and Urologic Oncology Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 51: Liver and Hepatobiliary Oncology Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 52: Lung and Thoracic Oncology Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 53: Colorectal and Gastrointestinal Oncology Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 54: Gynecologic and Other Solid Tumors Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 55: U.S. Minimally Invasive Oncology Devices Market: End User Snapshot, 2025
TABLE 56: Segment Dashboard; Definition and Scope, by End User
TABLE 57: U.S. Minimally Invasive Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 58: U.S. Minimally Invasive Oncology Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 59: Hospitals and Integrated Health Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 60: Comprehensive Cancer Centers and Academic Medical Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 61: Ambulatory Surgery Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 62: Interventional Radiology Centers and Outpatient Procedure Facilities Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 63: Specialty Urology, Gastroenterology, Pulmonology and Oncology Practices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 64: U.S. Minimally Invasive Oncology Devices Market: Technology Type Snapshot, 2025
TABLE 65: Segment Dashboard; Definition and Scope, by Technology Type
TABLE 66: U.S. Minimally Invasive Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 67: U.S. Minimally Invasive Oncology Devices Market: Segment Share Analysis, by Technology Type, 2025 & 2035 (%)
TABLE 68: Robotic-Assisted and Computer-Assisted Intervention Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 69: Thermal Ablation Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 70: Non-Thermal and Focused-Energy Ablation Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 71: Catheter-Based Transarterial Therapy Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 72: Image-Guided and Endoluminal Navigation Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 73: U.S. Minimally Invasive Oncology Devices Market: Procurement Channel Snapshot, 2025
TABLE 74: Segment Dashboard; Definition and Scope, by Procurement Channel
TABLE 75: U.S. Minimally Invasive Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 76: U.S. Minimally Invasive Oncology Devices Market: Segment Share Analysis, by Procurement Channel, 2025 & 2035 (%)
TABLE 77: Direct Hospital and Cancer Center Procurement Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 78: Integrated Delivery Network Enterprise Contracts Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 79: Group Purchasing Organization Contracts Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 80: Distributor and Specialty Supplier Sales Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 81: Ambulatory, Outpatient and Specialty Practice Procurement Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 82: U.S. Minimally Invasive Oncology Devices Market: Regional Snapshot, 2025
TABLE 83: Segment Dashboard; Definition and Scope, by Region
TABLE 84: U.S. Minimally Invasive Oncology Devices Market, by Region, 2021–2035 (US$ Billion)
TABLE 85: U.S. Minimally Invasive Oncology Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 86: U.S. Minimally Invasive Oncology Devices Market: Regional Cancer Procedure Volume and Hospital Infrastructure Analysis
TABLE 87: West Region U.S. Minimally Invasive Oncology Devices Market: Regional Overview and Trends
TABLE 88: West Region U.S. Minimally Invasive Oncology Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 89: West Region U.S. Minimally Invasive Oncology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 90: West Region U.S. Minimally Invasive Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 91: West Region U.S. Minimally Invasive Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 92: West Region U.S. Minimally Invasive Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 93: West Region U.S. Minimally Invasive Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 94: West Region U.S. Minimally Invasive Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 95: California Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 96: Washington Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 97: Arizona Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 98: Colorado Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 99: Oregon Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 100: Utah Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 101: Nevada Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 102: New Mexico Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 103: Idaho Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 104: Montana Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 105: Wyoming Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 106: Alaska Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 107: Hawaii Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 108: Northeast Region U.S. Minimally Invasive Oncology Devices Market: Regional Overview and Trends
TABLE 109: Northeast Region U.S. Minimally Invasive Oncology Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 110: Northeast Region U.S. Minimally Invasive Oncology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 111: Northeast Region U.S. Minimally Invasive Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 112: Northeast Region U.S. Minimally Invasive Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 113: Northeast Region U.S. Minimally Invasive Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 114: Northeast Region U.S. Minimally Invasive Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 115: Northeast Region U.S. Minimally Invasive Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 116: New York Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 117: Massachusetts Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 118: New Jersey Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 119: Pennsylvania Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 120: Connecticut Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 121: Maine Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 122: Vermont Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 123: New Hampshire Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 124: Rhode Island Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 125: Delaware Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 126: South Region U.S. Minimally Invasive Oncology Devices Market: Regional Overview and Trends
TABLE 127: South Region U.S. Minimally Invasive Oncology Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 128: South Region U.S. Minimally Invasive Oncology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 129: South Region U.S. Minimally Invasive Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 130: South Region U.S. Minimally Invasive Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 131: South Region U.S. Minimally Invasive Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 132: South Region U.S. Minimally Invasive Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 133: South Region U.S. Minimally Invasive Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 134: Texas Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 135: Florida Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 136: Georgia Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 137: North Carolina Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 138: Tennessee Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 139: South Carolina Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 140: Alabama Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 141: Mississippi Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 142: Louisiana Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 143: Arkansas Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 144: Kentucky Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 145: Oklahoma Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 146: Virginia Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 147: Maryland Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 148: West Virginia Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 149: Midwest Region U.S. Minimally Invasive Oncology Devices Market: Regional Overview and Trends
TABLE 150: Midwest Region U.S. Minimally Invasive Oncology Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 151: Midwest Region U.S. Minimally Invasive Oncology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 152: Midwest Region U.S. Minimally Invasive Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 153: Midwest Region U.S. Minimally Invasive Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 154: Midwest Region U.S. Minimally Invasive Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 155: Midwest Region U.S. Minimally Invasive Oncology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 156: Midwest Region U.S. Minimally Invasive Oncology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 157: Illinois Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 158: Ohio Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 159: Michigan Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 160: Minnesota Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 161: Indiana Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 162: Wisconsin Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 163: Missouri Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 164: Iowa Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 165: Kansas Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 166: Nebraska Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 167: North Dakota Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 168: South Dakota Minimally Invasive Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 169: U.S. Minimally Invasive Oncology Devices Market: Competitive Landscape Snapshot, 2025
TABLE 170: U.S. Minimally Invasive Oncology Devices Market: Key Company Market Share Analysis, 2025
TABLE 171: U.S. Minimally Invasive Oncology Devices Market: Company Positioning Matrix
TABLE 172: U.S. Minimally Invasive Oncology Devices Market: Product Portfolio Benchmarking of Key Players
TABLE 173: U.S. Minimally Invasive Oncology Devices Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 174: Intuitive Surgical, Inc.: Company Profile
TABLE 175: Medtronic plc: Company Profile
TABLE 176: Johnson & Johnson MedTech: Company Profile
TABLE 177: Boston Scientific Corporation: Company Profile
TABLE 178: Stryker Corporation: Company Profile
TABLE 179: Olympus Corporation: Company Profile
TABLE 180: FUJIFILM Healthcare: Company Profile
TABLE 181: KARL STORZ SE & Co. KG: Company Profile
TABLE 182: Siemens Healthineers: Company Profile
TABLE 183: GE HealthCare: Company Profile
TABLE 184: Philips: Company Profile
TABLE 185: Canon Medical Systems USA: Company Profile
TABLE 186: AngioDynamics, Inc.: Company Profile
TABLE 187: HistoSonics, Inc.: Company Profile
TABLE 188: EDAP TMS S.A.: Company Profile
TABLE 189: Profound Medical Corp.: Company Profile
TABLE 190: IceCure Medical Ltd.: Company Profile
TABLE 191: Terumo Corporation: Company Profile
TABLE 192: Merit Medical Systems, Inc.: Company Profile
TABLE 193: Sirtex Medical: Company Profile
TABLE 194: Cook Medical: Company Profile
TABLE 195: BD: Company Profile
TABLE 196: Teleflex Incorporated: Company Profile
TABLE 197: CONMED Corporation: Company Profile
TABLE 198: U.S. Minimally Invasive Oncology Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 199: U.S. Minimally Invasive Oncology Devices Market: Disruptive Technologies Impact Matrix
TABLE 200: Histotripsy and Incisionless Tumor Destruction Opportunity Analysis
TABLE 201: Next-Generation Robotic Oncology Surgery Platform Opportunity Analysis
TABLE 202: Irreversible Electroporation and Focal Cancer Therapy Opportunity Analysis
TABLE 203: Robotic Bronchoscopy and Endoluminal Intervention Opportunity Analysis
TABLE 204: AI-Assisted Image Guidance and Procedural Navigation Opportunity Analysis
TABLE 205: Advanced Microwave and Cryoablation Platform Opportunity Analysis
TABLE 206: Personalized and Image-Guided Radioembolization Opportunity Analysis
TABLE 207: U.S. Minimally Invasive Oncology Devices Market: Emerging Business Trends
TABLE 208: U.S. Minimally Invasive Oncology Devices Market: Business Opportunities for Startups and Existing Players
TABLE 209: U.S. Minimally Invasive Oncology Devices Market: Investment Prioritization Matrix
TABLE 210: U.S. Minimally Invasive Oncology Devices Market: Procedure Migration Opportunity Matrix
TABLE 211: U.S. Minimally Invasive Oncology Devices Market: Emerging Technology Adoption Timeline, 2026–2035
TABLE 212: U.S. Minimally Invasive Oncology Devices Market: Strategic Recommendations for Device Manufacturers
TABLE 213: U.S. Minimally Invasive Oncology Devices Market: Strategic Recommendations for Hospitals and Integrated Health Systems
TABLE 214: U.S. Minimally Invasive Oncology Devices Market: Strategic Recommendations for Comprehensive Cancer Centers
TABLE 215: U.S. Minimally Invasive Oncology Devices Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 216: U.S. Minimally Invasive Oncology Devices Market: Strategic Recommendations for Distributors and Channel Partners
TABLE 217: U.S. Minimally Invasive Oncology Devices Market: Strategic Recommendations for New Entrants and Startups
TABLE 218: U.S. Minimally Invasive Oncology Devices Market: Go-to-Market Strategy Considerations
TABLE 219: U.S. Minimally Invasive Oncology Devices Market: Product Positioning and Portfolio Expansion Guidance
TABLE 220: U.S. Minimally Invasive Oncology Devices Market: Clinical Evidence Generation Strategy
TABLE 221: U.S. Minimally Invasive Oncology Devices Market: Reimbursement and Market Access Strategy
TABLE 222: U.S. Minimally Invasive Oncology Devices Market: State-Level Commercial Prioritization Strategy
TABLE 223: U.S. Minimally Invasive Oncology Devices Market: Partnership, Licensing and M&A Opportunity Framework
TABLE 224: U.S. Minimally Invasive Oncology Devices Market: Scope Limitation
TABLE 225: U.S. Minimally Invasive Oncology Devices Market: Data Use Limitation
TABLE 226: U.S. Minimally Invasive Oncology Devices Market: Forecasting Limitation
TABLE 227: U.S. Minimally Invasive Oncology Devices Market: Legal Disclaimer
TABLE 228: U.S. Minimally Invasive Oncology Devices Market: Third-Party Data Disclaimer

List of Figures

FIGURE 1: U.S. Minimally Invasive Oncology Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: Market Ecosystem and Stakeholder Framework
FIGURE 4: U.S. Minimally Invasive Oncology Devices Market Executive Snapshot, 2025
FIGURE 5: Market Attractiveness Analysis
FIGURE 6: U.S. Minimally Invasive Oncology Devices Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 7: U.S. Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 8: U.S. Minimally Invasive Oncology Devices Market Year-wise Growth Curve, 2021–2035
FIGURE 9: High-Growth Opportunity Areas
FIGURE 10: Market Dynamics
FIGURE 11: Innovation & Patent Landscape, 2021–2025
FIGURE 12: Clinical Workflow Economics Framework
FIGURE 13: Hospital Capital Procurement Decision Framework
FIGURE 14: Oncology Procedure Migration to Outpatient Settings
FIGURE 15: PESTEL Analysis
FIGURE 16: Porter’s Five Forces Analysis
FIGURE 17: Value Chain Analysis
FIGURE 18: Supply Chain Analysis
FIGURE 19: FDA Regulatory and CMS Reimbursement Framework
FIGURE 20: Hospital Value Analysis Committee Decision Framework
FIGURE 21: Product Category Segment Market Share Analysis, 2025 & 2035
FIGURE 22: Product Category Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 23: Robotic and Laparoscopic Oncology Surgical Devices Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 24: Tumor Ablation Devices Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 25: Embolization and Radioembolization Devices Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 26: Endoscopic and Endoluminal Oncology Devices Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 27: Oncology Biopsy, Access, Navigation and Procedural Support Devices Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 28: Application Segment Market Share Analysis, 2025 & 2035
FIGURE 29: Application Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 30: Prostate and Urologic Oncology Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 31: Liver and Hepatobiliary Oncology Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 32: Lung and Thoracic Oncology Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 33: Colorectal and Gastrointestinal Oncology Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 34: Gynecologic and Other Solid Tumors Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 35: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 36: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 37: Hospitals and Integrated Health Systems Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 38: Comprehensive Cancer Centers and Academic Medical Centers Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 39: Ambulatory Surgery Centers Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 40: Interventional Radiology Centers and Outpatient Procedure Facilities Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 41: Specialty Urology, Gastroenterology, Pulmonology and Oncology Practices Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 42: Technology Type Segment Market Share Analysis, 2025 & 2035
FIGURE 43: Technology Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 44: Robotic-Assisted and Computer-Assisted Intervention Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 45: Thermal Ablation Technologies Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 46: Non-Thermal and Focused-Energy Ablation Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 47: Catheter-Based Transarterial Therapy Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 48: Image-Guided and Endoluminal Navigation Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 49: Procurement Channel Segment Market Share Analysis, 2025 & 2035
FIGURE 50: Procurement Channel Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 51: Direct Hospital and Cancer Center Procurement Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 52: Integrated Delivery Network Enterprise Contracts Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 53: Group Purchasing Organization Contracts Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 54: Distributor and Specialty Supplier Sales Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 55: Ambulatory, Outpatient and Specialty Practice Procurement Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 56: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 57: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 58: Regional Cancer Procedure Volume and Hospital Infrastructure Analysis
FIGURE 59: West Region U.S. Minimally Invasive Oncology Devices Market Share and Leading Players, 2025
FIGURE 60: West Region Market Share Analysis by State, 2025
FIGURE 61: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 62: California Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 63: Washington Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 64: Arizona Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 65: Colorado Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 66: Oregon Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 67: Utah Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 68: Nevada Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 69: New Mexico Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 70: Idaho Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 71: Montana Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 72: Wyoming Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 73: Alaska Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 74: Hawaii Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 75: Northeast Region U.S. Minimally Invasive Oncology Devices Market Share and Leading Players, 2025
FIGURE 76: Northeast Region Market Share Analysis by State, 2025
FIGURE 77: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 78: New York Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 79: Massachusetts Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 80: New Jersey Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 81: Pennsylvania Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 82: Connecticut Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 83: Maine Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 84: Vermont Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 85: New Hampshire Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 86: Rhode Island Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 87: Delaware Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 88: South Region U.S. Minimally Invasive Oncology Devices Market Share and Leading Players, 2025
FIGURE 89: South Region Market Share Analysis by State, 2025
FIGURE 90: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 91: Texas Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 92: Florida Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 93: Georgia Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 94: North Carolina Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 95: Tennessee Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 96: South Carolina Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 97: Alabama Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 98: Mississippi Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 99: Louisiana Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 100: Arkansas Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 101: Kentucky Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 102: Oklahoma Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 103: Virginia Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 104: Maryland Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 105: West Virginia Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 106: Midwest Region U.S. Minimally Invasive Oncology Devices Market Share and Leading Players, 2025
FIGURE 107: Midwest Region Market Share Analysis by State, 2025
FIGURE 108: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 109: Illinois Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 110: Ohio Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 111: Michigan Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 112: Minnesota Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 113: Indiana Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 114: Wisconsin Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 115: Missouri Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 116: Iowa Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 117: Kansas Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 118: Nebraska Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 119: North Dakota Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 120: South Dakota Minimally Invasive Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 121: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 122: Company Positioning Matrix
FIGURE 123: Key Player Product Portfolio Benchmarking
FIGURE 124: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 125: Minimally Invasive Oncology Device Innovation Roadmap
FIGURE 126: Histotripsy and Incisionless Tumor Treatment Adoption Roadmap
FIGURE 127: Next-Generation Robotic Oncology Surgery Opportunity Map
FIGURE 128: Irreversible Electroporation and Focal Therapy Growth Roadmap
FIGURE 129: Robotic Bronchoscopy and Endoluminal Oncology Opportunity Map
FIGURE 130: AI-Assisted Image Guidance and Navigation Technology Roadmap
FIGURE 131: Future Market Scenario Analysis, 2026–2035
FIGURE 132: Disruptive Technologies Impact Matrix
FIGURE 133: Emerging Business Trends Matrix
FIGURE 134: Investment Prioritization Matrix
FIGURE 135: Oncology Procedure Migration Opportunity Matrix
FIGURE 136: Emerging Technology Adoption Timeline, 2026–2035
FIGURE 137: Strategic Growth Roadmap for U.S. Minimally Invasive Oncology Device Companies
FIGURE 138: Go-to-Market Strategy Framework
FIGURE 139: Product Positioning and Portfolio Expansion Framework
FIGURE 140: Clinical Evidence and Reimbursement Strategy Framework
FIGURE 141: U.S. State-Level Commercial Prioritization Framework
FIGURE 142: Partnership, Licensing and M&A Opportunity Framework
FIGURE 143: Report Scope and Disclaimer Framework